Funding will support continued development of Calpurbatug (TRL1068), a novel therapy being evaluated for prosthetic joint infections (PJI) REDWOOD CITY, Calif., July 16, 2026 /PRNewswire/ -- Trellis ...
Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
Tech Times on MSN
Merck's Lipfendra becomes first oral cholesterol pill to match injectable PCSK9 potency
Oral PCSK9 inhibitor Lipfendra (enlicitide) won FDA approval July 16, 2026 as the first pill to match injectable cholesterol ...
Vir Biotechnology has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for ...
One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX®-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in ...
Dozens of research teams around the world are working to halt, treat and even prevent Alzheimer's disease, which silently ...
The antibody uses a dual mechanism of action and works to block the interaction between TSLP and its receptor.
Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers due to its aggressive biology and ...
Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.
FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein C-III-directed antisense oligonucleotide ...
FDA Drug Approvals and Regulatory Updates The table below is a review of notable updates that occurred in June 2026 for investigational products in development (not an inclusive list). Click on the ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results